Clinical Trial

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like muscle, fat, or nerves). In both cancer types the cancer must have already been treated, but has come back or spread, and cant be removed by surgery
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-16
notable Trial sites expanded: 0 -> 6 locations 2026-07-16
Trial Details
NCT Number NCT07602777
Lead Sponsor GlaxoSmithKline
Conditions Sarcoma
Enrollment 113 participants
Start Date 2026-06-22
Primary Completion 2027-11-18 (estimated)
Study Completion 2029-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-15